Login to Your Account



Cuban-discovered lung cancer vaccine heading to U.S. phase III; Bioven lands marketing option

By Nuala Moran
Staff Writer

Tuesday, July 12, 2016

LONDON – Bioven Europe Ltd. has taken an option on U.S. marketing rights to the Cuban-discovered lung cancer vaccine EGF-PTI, as it moves to extend the pivotal phase III trial to the U.S.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription